Introduction {#s1}
============

Aripiprazole (ARI; OPC-14597), a derivative of a dopamine (DA) autoreceptor agonist OPC-4392, is considered as an effective antipsychotic drug with a controversial mechanism of action ([@CIT0020]; [@CIT0021]). Compared with other antipsychotics, ARI has a safe and tolerable side-effect profile that includes low potential for extrapyramidal symptoms, weight gain, prolactin elevation, and sedation ([@CIT0018]). Because of its clinical efficacy and little chance to provoke adverse events during the therapeutic process, a lot of research has been addressed to explain the unique properties of ARI as well as to supply a solid basis for developing a new generation of antipsychotics. According to these observations, ARI seems to be a DA D~2~ receptor partial agonist with high affinity binding to many G protein coupled receptors, such as serotonergic, adrenergic, and histaminergic receptors ([@CIT0030]). It is believed that the partial agonism of ARI at D~2~ receptor would be the main explanation for its unique clinical profile. Nevertheless, partial agonism at serotonin (5-HT) receptors 5-HT~1A~ and 5-HT~2C~ and antagonism at 5-HT~2A~ may contribute to its special characteristics ([@CIT0017]; [@CIT0030]; [@CIT0002]). In addition, increasing evidence makes it difficult to consider ARI as a simple D~2~ partial agonist. Thus, the functional action of ARI at DA D~2~ receptors may vary among agonist, partial agonist, or antagonist depending upon the assessment system, the cell type selected, the function examined, the receptor density, the receptor reserve levels ([@CIT0030], [@CIT0032]), D~2~-D~3~ heteromerization (Maggio and Millan, 2009), or the surrounding environment, which likely differs between brain regions ([@CIT0013]). The concept of "functional selectivity" that was proposed by [@CIT0017] and well addressed by [@CIT0036] to interpret the unique behavior of ARI at D~2~ receptor seems more appropriate than simply considering it as a partial agonist.

[@CIT0012] demonstrated the apparent inconsistency of the behavior of ARI at D~2~ presynaptic autoreceptors and D~2~ postsynaptic receptors, as it seems to perform as an agonist at the former while as an antagonist at the latter. The antagonism at postsynaptic D~2~ receptors has been accepted as a way of controlling symptoms of schizophrenia, based on the therapeutic effect of conventional antipsychotics in treating positive symptoms ([@CIT0021]). Additionally, activation of D~2~ autoreceptors might also be beneficial for the treatment of some symptoms of schizophrenia ([@CIT0035]), although this agonistic effect of ARI is controversial, as it appears to be quite dependent upon the surrounding conditions like receptor density or receptor reserve ([@CIT0033], [@CIT0034]). Most of these reports were done in cell lines transfected with a high density of D~2S~ receptor, which is the main subtype of the D~2~ autoreceptors ([@CIT0038]). Also, the dopaminergic tone in the surrounding milieu has proved to be very important for evidencing the agonistic profile of ARI ([@CIT0007]). The functional actions of ARI at cloned human D~2~-DA receptors show a range of actions (agonism, partial agonism, antagonism) depending upon the cell type and function examined ([@CIT0017]; [@CIT0030]). Thus, more reliable evidence from noncloned, native receptor systems is needed to shed light on ARI actions *in vivo*.

In our laboratory, we have developed a method that allows measuring the DA synthesized in dopaminergic neuron terminals in a relatively short period of time ([@CIT0006]). Because this is a presynaptic response, it is regulated by the D~2~-like autoreceptors located on dopaminergic terminals. Thus, the stimulation or blockade of D~2~ autoreceptors will be reflected as changes in DA synthesis. By using this method in the present study, we monitored the direct functional effect of ARI at D~2~-like autoreceptors under a low or relatively higher dopaminergic tone elicited by modifying K^+^ concentrations.

Materials and Methods {#s2}
=====================

Materials {#s3}
---------

ARI was kindly provided by Otsuka Pharmaceutical Co. Ltd. (Tokyo, Japan). (-)-Quinpirole hydrochloride (QUIN) and (*S*)-(-)-sulpiride were from Tocris Bioscience (Minneapolis, MN). Opti-Phase Hisafe-3 liquid scintillation cocktail and \[3, 5 - ^3^H\]-L-tyrosine (40--60 Ci/mmol) were supplied by PerkinElmer Wallac (Turku, Finland). ARI and sulpiride were dissolved in ethanol at 10mM and diluted with water and QUIN was dissolved in water. \[3, 5- ^3^H\]-L-tyrosine was purified by high-performance liquid chromatography (HPLC) before use. Preclamol (S-(-)-PPP), ethylenediaminetetraacetic acid (EDTA), HPLC standards and other reagents were purchased from Sigma/RBI (Steinheim, Germany).

\[^3^H\]-DA Synthesis {#s4}
---------------------

Protocols for animal handling were previously approved by the Ethics Committee for Human and Animal Research (Universitat Autònoma de Barcelona) in accordance with the European Communities Council Directive of 24 November 1986(86/609/EEC). The procedure used was previously described ([@CIT0006]). Male Sprague-Dawley rats of 200 to 250g (Servei d'Estabulari, Universitat Autonoma de Barcelona, Spain) were killed by decapitation between 10:00 and 11:00 [am]{.smallcaps}. Brains were taken out immediately and chilled in modified Krebs-Ringer-bicarbonate medium with the following composition: 120mM NaCl, 0.8mM KCl, 2.6mM CaCl~2~, 0.67mM MgSO~4~, 1.2mM KH~2~PO~4~, 27.5mM NaHCO~3~, and 10mM glucose, pH 7.4, saturated with 95% O~2~ / 5% CO~2~. In a 4ºC room, striata (including nucleus accumbens) were dissected and sliced using a McIlwain tissue chopper to obtain minces with a shape that approximates cubes of 0.3×0.3mm/side. Minces were suspended in the same medium and washed by centrifugation and resuspension to remove cell debris. Tissue minces were distributed into 2-mL polypropylene tubes and preincubated for 2 hours at 37°C in an Eppendorf Thermomixer under 95% O~2~ / 5% CO~2~ atmosphere. ARI, QUIN, S-(-)-PPP, or vehicle were added at the latest 10 minutes of preincubation. Then ring-labeled \[3, 5- ^3^H\]-L-tyrosine (40--60 Ci/mmol) was added to all samples (final concentration of 0.12 μM), and incubation continued for 10 minutes more to synthesize \[^3^H\]-DA. A depolarizing condition was obtained by increasing the K^+^ in the Krebs buffer by adding concentrated KCl. This depolarizing medium was added 10 minutes before ARI or QUIN. When the D~2~ antagonist sulpiride was used, it was added 10 minutes before ARI or QUIN. The synthesis was stopped by the addition of a deproteinizing solution containing trichloroacetic acid and 100 nmol internal standard DA per tube. Blank tubes contained deproteinizing solution prior to addition of \[^3^H\]-tyrosine and were kept ice-cold throughout. All samples were homogenized in a Dynatech/Sonic Dismembrator (Dynatech Labs, Chantilly, VA). An aliquot was taken for protein quantification by the Lowry method to take into account the variability of tissue amounts in each tube. Tissue homogenates were then centrifuged (12,000 *g*, 10 minutes, 4°C), and supernatants were recovered for \[^3^H\]-DA purification by HPLC-UV.

The chromatographic system consisted of a reverse-phase C~18~ column (Tracer Extrasil ODS2, 5-μm particle size, 25x0.46cm; Teknokroma, Spain) and an ion-pair mobile phase made of 100mM sodium phosphate buffer, 1mM EDTA, and 0.75mM octanesulfonic acid plus 12 % (vol/vol) methanol at pH 5. Flow rate was 1mL/min. Internal standards were detected by UV 285nm. Radiolabelled and endogenous tyrosine and DA were undetectable by UV absorbance. Recovery of the internal standard was quantified in each sample (internal/external standard peak area). DA fractions were collected in scintillation vials, mixed with Optiphase HiSafe III cocktail, and \[^3^H\]-DA was quantified in a liquid scintillation counter. Disintegrations per minute (dpm) obtained were corrected by DA internal standard recovery, dpm in blank samples, and protein content in each incubated tube. Results were expressed as percentage vs control samples in the same experiment. Concentration-response curves were obtained after normalization to percent of controls in the same experiment, pooling of data, and nonlinear fit to sigmoidal dose response. The concentration curve of ARI in 2mM K^+^ was best fitted to a 2-site competition curve.

Results {#s5}
=======

10 nM ARI Inhibits DA Synthesis through D~2~-Like Receptors under 2mM K^+^(Basal Conditions) {#s6}
--------------------------------------------------------------------------------------------

Activation of D~2~ receptors can inhibit DA synthesis in dopaminergic neurons in rat brain striatum. To confirm this, the well-known D~2~ receptor agonist quinpirole (QUIN) was used as a standard reference. Under 2mM K^+^ (basal condition), QUIN decreased DA synthesis in a dose-dependent manner. As shown in [Figure 1a](#F1){ref-type="fig"}, QUIN effects followed a 1-site model with the following parameters: Emax=47.8±0.42%; EC50=11.4nM. This effect was totally blocked by the selective D~2~ receptor antagonist sulpiride (data not shown).

![Concentration-response curve of quinpirole (QUIN) (a) and aripiprazole (ARI) (b) on the inhibition of dopamine (DA) synthesis in nonstimulated rat brain striatal minces (basal condition: 2mM K^+^). Experimental design is shown in the time bar under the graph. Data represent the means ± SEM of N incubations indicated over the symbols. ^*\**^ *P*\<.05, ^*\*\**^ *P*\<.01, and ^*\*\*\**^ *P*\<.001 vs control (1-way ANOVA followed by Bonferroni's test). Data were fitted to a sigmoidal dose-response (a) or a 2-site competition (b) curve. Parameters obtained are listed in [Table 1](#T1){ref-type="table"}.](ijnppy_pyu046_f0001){#F1}

###### 

Parameters of Quinpirole, Aripiprazole, and S-(-)-PPP Inhibition of Rat Brain \[^3^H\]-Dopamine Synthesis under Basal (2mM K^+^) or Stimulated (15mM K^+^) Conditions Representing Low- and High-Dopaminergic Tone, Respectively

                                   2mM K^+^           15mM K^+^
  -------------------------------- ------------------ -----------
  Quinpirole                                          
   IC~50~, nM                      11                 9.3
   Emax, %                         49                 39
  Aripiprazole                                        
   IC~50~ (1st/2nd component)      0.93nM / 0.21 µM   68 nM
   Emax (1st / 2nd component), %   41/69              17
  Preclamol (S-(-)-PPP)                               
   IC~50~, nM                      0.11               0.051
   Emax, %                         34                 31

Under the same experimental conditions, we obtained the concentration-response curve of ARI on the inhibition of DA synthesis shown in [Figure 1b](#F1){ref-type="fig"}. Unlike the dose-response curve of QUIN, this curve best fitted with a 2-site model with the following parameters: Emax=69±0.43%, EC50~1~=0.93nM, and EC50~2~=0.21 µM ([Table 1](#T1){ref-type="table"}). Compared with the QUIN dose curve, we made the hypothesis that only the first part of the ARI dose-response curve was due to its effects on D~2~ autoreceptors. To test this hypothesis, the typical selective D~2~ receptor antagonist sulpiride was applied to block D~2~ receptors. Sulpiride at 1 μM fully eliminated the inhibitory effect of ARI at 10nM on DA synthesis, which was consistent with our hypothesis ([Figure 2a](#F2){ref-type="fig"}). In addition, QUIN failed to make a concentration-related response when added to the incubations 10 minutes after ARI 10nM, as shown in [Figure 2b](#F2){ref-type="fig"}. The comparisons between the 2 dose-response curves of QUIN (one in the absence and the other in the presence of ARI 10nM; [Figure 2b](#F2){ref-type="fig"}) indicate that the D~2~ autoreceptors have already been activated by ARI 10nM. These data strengthen our hypothesis that low doses (≤100nM) of ARI inhibit DA synthesis due to its action on D~2~-like receptors. To further address this issue, we examined whether the effects of a higher concentration of ARI (1 μM) could be blocked by sulpiride. Sulpiride (1 μM) partially blocked the effect of 1 µM ARI (from −50% to −32%; [Figure 2c](#F2){ref-type="fig"}), but could not eliminate it completely. Thus, it is likely that micromolar concentrations of ARI inhibit DA synthesis through D~2~ and non-D~2~ mediated mechanisms.

![Inhibition of dopamine (DA) synthesis by 10nM aripiprazole (ARI) is mediated by D~2~ receptors. a, Striatal minces were incubated with sulpiride (1 μM) and ARI (10nM) either alone or together under a 2-mM K^+^ condition. Sulpiride 1 µM could totally eliminate the effect of ARI at 10nM. b, Concentration-response curve of quinpirole (QUIN) in the presence of 10nM ARI under a 2-mM K^+^ condition. C, Sulpiride at 1 μM only partially blocks the inhibitory effect of ARI at 1 μM. Striatal minces were incubated under 2mM K^+^. Experimental design is shown in a time bar under each graph. Data represent the means ± SEM of N incubations indicated by the symbols or inside bars. ^*&*^ *P*\<.001 vs control, ^*\#*^ *P*\<.001 vs group treated with both ARI 10nM and sulpiride 1 μM; *\*P*\<.05 and *\*\*\*P*\<.001 vs group treated in the absence of ARI at the same dose. c, Statistical difference between both ARI-treated groups is expressed by a connecting line (1-way ANOVA followed by Bonferroni's test).](ijnppy_pyu046_f0002){#F2}

ARI Failed to Activate D~2~Autoreceptors under 15mM K^+^(Stimulated Conditions) {#s7}
-------------------------------------------------------------------------------

Increasing the potassium concentration in Krebs buffer from 2 to 15mM increased the amount of DA released, as expected. In preliminary experiments, the percent of newly synthesized \[^3^H\]-DA released to the medium under 2mM K^+^ was 1.13±0.95% (mean±SD, N=23 incubations) while under 15mM K^+^ was 7.5±3.0% (N=38 incubations). This led to a 6.6-fold increase in DA released. The increased concentrations of extracellular DA may facilitate its interaction with D~2~ autoreceptors. Previous reports have shown that the dopaminergic tone played a very important role in evidencing the agonist property of ARI ([@CIT0007]). Similarly, in our present study, we also observed different effects of ARI under different extracellular DA concentrations, which could also represent differences in the dopaminergic tone ([Table 1](#T1){ref-type="table"}; [Figure 3](#F3){ref-type="fig"}). Under 15mM potassium conditions, ARI failed to inhibit DA synthesis at doses \<10 μM ([Figure 3b](#F3){ref-type="fig"}). We also measured the effect of QUIN under the same situation. As a typical D~2~ agonist, QUIN acted as a stable agonist under both conditions, as the dose-response curve of QUIN under 15mM K^+^ was quite similar with the curve under 2mM K^+^ ([Figures 1a](#F1){ref-type="fig"} and [3a](#F3){ref-type="fig"}), and the parameters for the 2 curves did not differ much either ([Table 1](#T1){ref-type="table"}). The reason why ARI failed to stimulate D~2~ autoreceptors in the depolarizing conditions could be either because ARI failed to bind to D~2~ receptors in the presence of the high concentration of DA or because ARI managed to bind but failed to stimulate D~2~ receptors more efficiently than DA, behaving like an antagonist. To determine the reason, we treated the brain minces with both ARI and QUIN and observed that 10nM ARI could totally eliminate the effects of QUIN at either 10 or 100nM ([Figure 4](#F4){ref-type="fig"}). These results prove that ARI binds D~2~ receptors under these conditions but behaves as an antagonist under high dopaminergic tone. This result is fully consistent with a high affinity and low efficacy of ARI for the stimulation of D~2~ receptors. Moreover, in the presence of 15mM K^+^, 10nM ARI tended to increase DA synthesis ([Figure 4](#F4){ref-type="fig"}), as it would be expected for an antagonist of K^+^-released DA. To further characterize the influence of K^+^ in the properties of ARI, we gradually increased K^+^ concentrations from 2 to 15mM K^+^ to increase the probability of DA release and tested the agonism elicited by 100nM ARI. We found that under a 8-mM K^+^ threshold, ARI had agonist effects ([Figure 5](#F5){ref-type="fig"}). These effects appeared full or partial depending on K^+^ concentrations and were clearly lost at higher K^+^. It seems likely that a higher extracellular DA concentration rendered ARI unable to stimulate D~2~ receptors more efficiently than the endogenous neurotransmitter, although alternative effects of depolarization on membrane environment cannot be ruled out ([@CIT0027]).

![Concentration-response curve of quinpirole (QUIN) (a) and aripiprazole (ARI) (b) on the inhibition of dopamine (DA) synthesis in stimulated rat brain striatal minces (high-dopaminergic tone condition: 15mM K^+^). Experimental design is shown in the time bar under each graph. Data represent the means ± SEM of N incubations indicated by the symbols. ^*\**^ *P*\<.05, ^*\*\**^ *P*\<.01, and ^*\*\*\**^ *P*\<.001 vs control (1-way ANOVA followed by Bonferroni's test). Data were fitted to a sigmoidal dose-response curve. Parameters obtained are listed in [Table 1](#T1){ref-type="table"}.](ijnppy_pyu046_f0003){#F3}

![10nM aripiprazole (ARI) blocks quinpirole (QUIN) inhibition of dopamine (DA) synthesis under 15-mM K^+^ conditions. Minces were treated with ARI (10nM) and QUIN (10 and 100nM) either alone or together. Experimental design is shown in the time bar under the graph. Data represent the means ± SEM of N incubations indicated inside the bars. *\*P*\<.05 vs blank control. ^*\#*^ *P*\<.05 and ^*&*^ *P*\<.05 in the 2 groups of connected bars (1-way ANOVA followed by Bonferroni's test).](ijnppy_pyu046_f0004){#F4}

![Titration of aripiprazole (ARI) effects on dopamine (DA) synthesis vs increasing K^+^ concentrations. ARI (100nM) behaved as an agonist with K^+^ concentrations up to 6mM in our brain minces incubations. Experimental design is shown in the time bar under the graph. Data shown represent means ± SEM of N incubations indicated over the symbols, normalized to the respective control group under the same K^+^ concentration (not show in the graph). \**P*\<.05 and \*\*\**P*\<.001 vs control group under the same K^+^ concentration (1-way ANOVA followed by Bonferroni's test).](ijnppy_pyu046_f0005){#F5}

Comparison of the Effects of ARI with the Partial Agonist Preclamol (S-(-)-PPP) {#s8}
-------------------------------------------------------------------------------

Preclamol (S-(-)-PPP) has been extensively characterized as a D~2~ receptor partial agonist ([@CIT0004]; [@CIT0015]; [@CIT0031]). To assess whether the effects of ARI were unique to this compound or shared with other D~2~ partial agonists, we assayed the effects of S-(-)-PPP on DA synthesis under 2 and 15mM K^+^ conditions. We found that S-(-)-PPP did inhibit DA synthesis quite similarly in both situations ([Figure 6a](#F6){ref-type="fig"} and [b](#F6){ref-type="fig"}), with maximal effects (−34 and −31%, respectively) smaller than those of ARI or QUIN. Although such small maximal effects are consistent with literature data on S-(-)-PPP, the shape of the concentration response curve appeared biphasic, with significant decreases of DA synthesis at 1nM and 1 µM and some nonsignificant points at the high nanomolar range and 10 µM as well ([Figure 6](#F6){ref-type="fig"}). As the reported affinity of S-(-)-PPP for D~2~ receptors is in the high-nanomolar/low-micromolar range ([@CIT0004]; [@CIT0003]; [@CIT0031]), we were curious about the 1nM S-(-)-PPP significant effects. We found that the decrease in DA synthesis elicited by 1nM S-(-)-PPP was completely reversed by 100nM sulpiride ([Figure 6c](#F6){ref-type="fig"}). Thus, it seems likely that S-(-)-PPP elicits dual effects on DA synthesis quite different from those previously observed with ARI.

![The effects of the D~2~ partial agonist preclamol (S-(-)-PPP) differ from those of aripiprazole (ARI) previously shown. Concentration-response curves of S-(-)-PPP on the inhibition of dopamine (DA) synthesis in (a) nonstimulated (basal condition: 2mM K^+^) or (b) stimulated rat brain striatal minces (high-dopaminergic tone condition: 15mM K^+^). c, The effect of 1nM S-(-)-PPP is completely blocked by sulpiride (100nM). Experimental design is shown in the time bar under the graph. Data represent the means ± SEM of N incubations indicated over the symbols inside bars. \**P*\<.05 and \*\*\**P*\<.001 vs control. ^&^ *P*\<.001 vs control, ^\#^ *P*\<.001 vs group treated with both S-(-)-PPP 1nM and sulpiride 100nM (1-way ANOVA followed by Bonferroni's test). Data were fitted to a sigmoidal dose-response curve. Parameters obtained are listed in [Table 1](#T1){ref-type="table"}.](ijnppy_pyu046_f0006){#F6}

Discussion {#s9}
==========

In the present paper, we show that ARI actions on native D~2~-like autoreceptors in rat brain presynaptic dopaminergic terminals can be those of an agonist or an antagonist, depending on whether the experimental conditions mimic low or high dopaminergic tone. These results are consistent with the well-known low activity of ARI to stimulate D~2~ receptors that is characteristic of a partial agonist when compared with DA. However, we must note that important differences were found between ARI and preclamol (S-(-)-PPP), another well-characterized D~2~ receptor partial agonist that seems to work differently. The strength of these results is that we use an approach that can be considered more physiologically relevant than previous articles in receptor-transfected cells. First, D~2~ receptors involved were neuronal. Second, DA competing with ARI was released by K^+^ stimulation of brain tissue *ex vivo*. And finally, the response measured is \[^3^H\]-DA synthesis, a specific process of catecholaminergic neurons, mostly dopaminergic in the striatum. However, these strengths bring together the challenge of the correct interpretation of results obtained in this complex tissue sample, where other receptors and brain terminals and other cells are also naturally present.

Presynaptic D~2~ receptors are thought to be the D~2S~ subtype compared with the full-length D~2L~ subtype ([@CIT0038]). Previous work by [@CIT0012] suggested that the agonist or antagonist properties of ARI were dependent on the presynaptic vs postsynaptic localization of D~2~ receptors, respectively. However, here we show that ARI can show both agonist and antagonist properties at the same presynaptic location controlling DA synthesis. This indicates that the subtype of D~2~ receptor involved does not explain the switch in the behavior of ARI. In agreement, later work by Kikuchi's group ([@CIT0031], [@CIT0032], [@CIT0033], [@CIT0034]) found that ARI can be agonist and antagonist on recombinant human D~2S~ receptors, depending on the level of receptor expression and competing DA. Thus, our results validate in brain tissue the later hypothesis of these authors. Presynaptic D~2~-like receptors can be fully stimulated by ARI provided that competing DA is maintained at low levels. In contrast, during nerve terminal release of DA, ARI behaves as an antagonist because of its lower efficacy to stabilize the active conformation of D~2~ receptors compared with DA. The subtype of D~2~-like receptors controlling DA synthesis likely is the D~2S~, although a minor contribution of D~3~ receptors or postsynaptic D~2~ receptors cannot be completely ruled out ([@CIT0038]; [@CIT0001]).

Previous work also showed that the intrinsic activity of D~2~ partial agonists seems to depend on receptor reserve ([@CIT0022]; [@CIT0003]). A partial agonist like ARI might stabilize D~2~ receptors in a conformation that activates G proteins only for short periods or with low efficacy, leading to higher dissociation constants of the receptor-G protein complex. As a consequence, it may need to occupy significantly more receptors than the full agonist QUIN to reach a similar maximal agonist effect. These "extra" receptors available for the agonist properties of ARI can come from the so-called receptor reserve ([Figure 7](#F7){ref-type="fig"}). A higher receptor reserve has been hypothesized for presynaptic D~2~ receptors compared with postsynaptic D~2~ receptors ([@CIT0022]). Therefore, a partial agonist like ARI will appear to have higher intrinsic activity at presynaptic D~2~ receptors vs postsynaptic D~2~ receptors due to receptor reserve. This assumption fits experimental data ([@CIT0012]; [@CIT0003]). Nevertheless, a high receptor reserve is necessary but not sufficient for ARI to show its agonist properties: a low dopaminergic tone is also required. Previous papers showing agonist effects of ARI on DA synthesis required a low dopaminergic tone, achieved by reserpine or gamma-butyrolactone treatment to animals ([@CIT0012]; [@CIT0007]). Reserpine depletes DA stores, and gamma-butyrolactone is considered a nerve impulse inhibitor preventing DA release. In our work, an interruption of nerve impulses takes place at slicing striatal tissue by cutting off nerve endings from dopaminergic cells bodies. Therefore, our basal conditions (2mM K^+^) may well be considered relatively similar to gamma-butyrolactone in that they produce a low dopaminergic tone, where only 1% of newly synthesized \[^3^H\]-DA is released to the medium. Accordingly, we may wonder whether ARI is actually able to act as an agonist *in vivo*, where dopaminergic tone might be fluctuating within a range difficult to define. Indeed, human results suggest that ARI has actions consistent with agonism on D~2~ receptors controlling prolactin release, in contrast with most antipsychotics ([@CIT0026]). Whether ARI acts as a D~2~ agonist on nerve terminals involved in psychosis remains speculative, but it is worth considering, as it led to its discovery ([@CIT0012]). Beneficial effects of selective dopaminergic autoreceptor agonists have been postulated for the treatment of psychosis ([@CIT0035]). However, if a high dopaminergic tone is expected during psychosis, the antagonistic action of ARI on both pre- and postsynaptic D~2~ receptors will more likely prevail and correlate with its antipsychotic effects. On the other hand, the postulated "DA stabilization" elicited by ARI would only make sense on presynaptic D~2~ receptors, which have sufficient receptor reserve to account for ARI agonist and antagonist properties. The lower receptor reserve of postsynaptic D~2~ receptors would only allow antagonist-like effects of ARI, based on the lack of sufficient G protein activation. Therefore, postsynaptic "DA stabilization" would not be possible unless alterations in receptor sensitivity or functional selectivity add new levels of complexity to the postsynaptic actions of ARI ([@CIT0022]; [@CIT0020]; [@CIT0021]).

![Hypothetical model explaining the actions of partial agonists aripiprazole (ARI) and preclamol ((-)PPP) and the full agonist quinpirole (QUIN) on dopamine (DA) synthesis. Both partial agonists would mobilize the receptor reserve, as a difference with the full agonist quinpirole. The 2 partial agonists would, however, stabilize different conformations of the D~2~ receptors, leading to functional selectivity for signaling proteins. G1 and G2 could be different G proteins or other signaling molecules competing for binding to the active receptor. ARI would stimulate G1 only if a low-dopaminergic tone is present, since DA more efficiently activates D~2~ receptors than ARI.](ijnppy_pyu046_f0007){#F7}

The difference in maximal effects between ARI and S-(-)-PPP cannot be explained solely by the receptor reserve hypothesis. S-(-)-PPP usually shows higher intrinsic activity than ARI under several assays ([@CIT0003]; [@CIT0031]; [@CIT0010]), so we were surprised by the lower maximal effect of S-(-)-PPP compared with ARI (−34% vs −41%, respectively, at 2mM K^+^ ([Figure 6a](#F6){ref-type="fig"}; [Table 1](#T1){ref-type="table"}). Similarly, literature binding data show that the conformation of D~2~ receptors stabilized by ARI might be closer to that of a typical antagonist compared with that stabilized by S-(-)-PPP ([@CIT0003]; [@CIT0037]; but see also [@CIT0030]). Intrinsic activity of D~2~ receptor partial agonists depends on the assay used ([@CIT0010]), which could be due to functional selectivity vs several intracellular cascades and their respective amplification mechanisms ([@CIT0011]). The fact that in our functional assay ARI was more efficient than S-(-)-PPP may be an indication of preferred functional selectivity of ARI vs the transduction pathway inhibiting DA synthesis. In fact, [@CIT0023] found evidence of D~2~ agonists having the opposite functional selectivity, with poor effects on D~2~-controlled DA synthesis, which gives support to the functional selectivity hypothesis. In addition, we were also surprised by the shape of the concentration curve S-(-)-PPP, which suggests a complex interaction with receptors controlling DA synthesis. The rise of extracellular DA elicited by 15mM K^+^ does not seem to affect it, which is similar to QUIN, but not to ARI. Although a detailed study of S-(-)-PPP effects exceeds the scope of this paper, its effects seem to be D~2~ mediated ([Figure 6c](#F6){ref-type="fig"}; but see [@CIT0016]). Alternative explanations can be considered, such as better oligomerization of some receptor conformations than others, although at present this would be highly speculative ([@CIT0025]).

When DA release was stimulated by 15mM K^+^, nanomolar concentrations of ARI did not decrease \[^3^H\]-DA synthesis like QUIN or S-(-)-PPP, but instead they clearly blocked QUIN action, behaving as an antagonist. In addition, in the absence of QUIN, we observed a slight tendency to increase \[^3^H\]-DA synthesis in samples treated with ARI. This could reveal ARI antagonism of K^+^-released endogenous DA stimulating D~2~ receptors. We do not know how much of endogenous DA was released by 15mM K^+^ or the concentrations of extracellular DA achieved, because these values would be hard to obtain within the same experiment in our conditions. We know from preliminary experiments that the percent of newly synthesized \[^3^H\]-DA released by 15mM K^+^ increases by 6.6-fold on average compared with 2mM K^+^. We hypothesized that this K^+^ stimulation would model a higher dopaminergic tone in rat brain minces *ex vivo*, but we must acknowledge that membrane depolarization may also have additional effects on D~2~ receptor conformation and interactions with signaling molecules ([@CIT0027]). Furthermore, any comparison of our results with dopaminergic tone in human schizophrenics would be speculative. Nevertheless, we observed a remarkable switch of ARI behavior from agonist to antagonist by increasing K^+^. Therefore, our method could be useful for future pharmacological research of newer D~2/3~-based antipsychotics with low liability of side effects based on clinical experience with ARI. New compounds like brexpiprazole or cariprazine are being clinically tested. Additional D~2~ partial agonists already exist, but ARI has been the most clinically successful so far. An important question to consider on this issue is the degree of intrinsic efficacy of a partial agonist that is optimal for the best antipsychotic effects ([@CIT0035]). ARI is considered to have low intrinsic efficacy; that is, its activity is closer to that of an antagonist than to that of an agonist. Previous D~2~ partial agonists tested may have failed to display the adequate intrinsic activity for antipsychotic clinical effects ([@CIT0015]; [@CIT0031]; Natesan et al., 2010). An important additional question is whether there is a clear relationship between D~2~ partial agonism and low liability of extrapyramidal side effects. Two main hypotheses are currently being considered. First, D~2~ occupancy by antagonists might have a threshold over which extrapyramidal effects would appear. And second, transient D~2~ blockade would elicit less extrapyramidal side effects than continuous blockade ([@CIT0028]). Surprisingly, ARI occupancy of D~2~ receptors at clinically relevant doses has been shown to be well above the threshold considered for other antipsychotics, and ARI is not relatively fast at dissociating from D~2L~ receptors (Kuroki et al., 2002; [@CIT0029]; [@CIT0019]). This suggests that ARI action on D~2~ conformation might contribute to low liability of extrapyramidal effects. The low efficacy of ARI - D~2~ - G protein activation might not elicit significant postsynaptic responses, but it may allow a higher D~2~ receptor occupancy than other antipsychotics without producing extrapyramidal side effects.

Our determination of \[^3^H\]-DA synthesis in brain tissue *ex vivo* is methodologically faster than classical DOPA accumulation *in vivo*. We obtained 24 incubations of brain minces from the striata of a single rat. QUIN and ARI IC~50~ values obtained were very similar to those reported in the literature ([Table 1](#T1){ref-type="table"}). QUIN reached its maximal effect (48% decrease) at 100nM. In contrast, the maximal effect of ARI was a 68% decrease at the concentration 1 µM, with a curve best adjusted to 2 sites. ARI not only has affinity for D~2~ receptors, it also has significant affinity for a large number of other G-protein coupled receptors, such as serotonergic, adrenergic, and histaminergic receptors ([@CIT0030]). The low-affinity effect of ARI on \[^3^H\]-DA synthesis could be related to actions on serotonin or other receptors, as it has a higher IC~50~ than D~2~-mediated effects ([Table 1](#T1){ref-type="table"}) and it was not blocked by 1 μM sulpiride ([Figure 2c](#F2){ref-type="fig"}). The selective 5-HT~1A/7~ receptor agonist R(+)-8-OH-DPAT attenuates amphetamine-induced DA synthesis in rat striatum ([@CIT0014]), and also other agonists of 5-HT~1A~ receptors inhibit tyrosine hydroxylase in rat striatum ([@CIT0008]). We must note, however, that 5-HT~1A~ receptors are considered as somatodendritic and unlikely present in dopaminergic terminals. The serotonergic actions of ARI deserve further investigation, as they could contribute to its unique antipsychotic effects ([@CIT0009]; [@CIT0030]; [@CIT0002]). Here in our study, the non-D~2~ receptor effect of ARI on the inhibition of DA synthesis might be related with serotonin 5-HT~1A/7~, 5-HT~2C~ receptors, or receptors for additional neurotransmitters ([@CIT0005]; [@CIT0030]), but further studies are needed to confirm these hypotheses. The low presence of serotonergic receptors in dopaminergic terminals open the possibility that the non-D~2~ effects of ARI on DA synthesis are indirectly mediated by GABA or glutamate terminals also present in our minces of striatal tissue. This effect does not disappear under the 15mM K^+^ condition, which also differentiates it from D~2~-mediated effects.

In conclusion, we observed different properties of ARI under different levels of dopaminergic tone in the surrounding milieu: agonist under low dopaminergic tone and antagonist under a relatively higher dopaminergic tone elicited by increasing K^+^ concentrations. This can be based on the low activity of ARI as agonist and the high receptor reserve of presynaptic D~2~ autoreceptors, but the functional selectivity hypothesis must be taken into consideration, as it has different effects than S-(-)-PPP. In contrast, the D~2~ receptor full agonist QUIN acted as a clear agonist under both conditions. We also observed an effect of ARI at higher concentrations that is not apparently D~2~ mediated. These results indicate that ARI effects on presynaptic D~2~-like receptors in brain tissue have unique properties that clearly differentiate it from other traditional antipsychotics.
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